In recent decades, the world has witnessed an unprecedented decrease in child mortality, with numbers halving from the over 12.7 million annual child deaths in 1990 to less than 6 million in 2015 [1] . This decreasing tendency has been confirmed in all areas of the world, although reductions have been rather modest in developing countries and in particular in Sub-Saharan Africa. Neonatal deaths have also decreased but at a much slower rate, and thus account for an increasing proportion of child deaths (37.4% in 1990, 44% in 2013 [2] ). The first months of life seem therefore the most vulnerable period for the child's survival, and the global health community has the responsibility to specifically address major causes of premature death with adequate interventions designed to suit the needs of the younger ones. In low-income settings, however, the availability of specific paediatric formulations tailored to the particular needs of newborns and young children is severely limited [3] . The global scarcity of specific paediatric formulations is a well-recognized problem worldwide [4] , but its impact is maximum in the 54 countries of Africa, and more specifically related to the treatment of infections and other diseases endemic to the continent. Indeed, licensing a paediatric-friendly formulation includes the requirement of conducting in infants well-designed clinical trials, to assess the bioequivalence of this new formulation against the original one [5] . Palatability assessments should also be conducted, to understand how the taste of the new formulation may affect its acceptability. These trials are expensive and challenging to do in low-income settings [6] , and it does not come as a surprise that trials assessing specific paediatric formulations for 'tropical' diseases are only sporadically conducted.
The World Health organization (WHO) currently recommends the use of either dispersible tablets or granule sachets adjusted for size and strength as the preferred drug formulation for young children and infants [7] . However, with few exceptions, these types of formulations are hard to find in rural areas of the developing world, where populations seem to be entirely unfamiliar with their use [8] . Other formulations often used in children include liquid formulations (syrups), or oral suspensions (to be mixed with water), and seem to be more readily available and known by the population, but require manipulation or particular storage conditions (refrigeration) after preparation that make their use and stability in hot-climate rural areas particularly challenging. In the absence of adequate paediatric formulations, children in poor settings are often administered oral solid dosage forms originally tailored for adults, crushed and dissolved in water. These practices, and the frequently suboptimal palatability of adult medications, often lead to poor tolerability and compliance, and inaccurate dosing, which may increase the risk of toxicity, reduced efficacy and drug resistance [8] .
In recent years, several initiatives have been set up in the Western World to incentivize the specific development of paediatric formulations [9, 10] , but progress remains slow, particularly in terms of their translation into better drugs for the children of lowincome countries [11] . The WHO has recently [12] . This list is intended to guide therapeutic treatment for priority conditions for children up to 12 years of age, and is an excellent backbone for countries and their pharmacology/pharmacy specialists to work towards a more harmonized approach to paediatric therapeutics. More specific initiatives such as the WHO campaign 'make medicines child size' [13] [14] or malaria [15, 16] are opportune, but still insufficient.
Perhaps malaria and HIV/AIDS are two of the most paradigmatic examples of the challenges faced, but also of the significant successes achieved, in regards to the specific treatment of paediatric populations in poor settings. Malaria is an eminently paediatric condition, and most recent estimates [17] suggest that up to two thirds of the circa 438 000 malaria deaths globally occur in African children. Despite the tremendous achievements in the past decade in terms of malaria incidence and mortality reductions, infants and children infected still require better therapeutic tools. Since its licensure in 2009, over 250 million doses of the dispersible cherry-flavoured paediatric formulation of artemether-lumefantrine (Coartem Õ ) have been delivered in over 50 malaria-endemic countries [18] . Amodiaquine-artesunate (Winthrop/Coarsucam Õ ) has also an approved dispersible formulation, and within the next months two further paediatric-friendly formulations of dihydroartemisinin-piperaquine (dispersible, Eurartesim Õ ) and pyronaridine-artesunate (granules, Pyramax Õ ) should be made available. The relatively recent success story of malaria treatment in children is worth imitating.
In relation to HIV/AIDs, challenges remain significant to reverse the paediatric burden imposed by this pandemic. It has been estimated that, despite great progresses in the scale-up of antiretroviral treatments, 240 000 children still became infected with HIV in 2013 [19] . Current treatment guidelines proposed by WHO clearly recommend that all children diagnosed with HIV should start treatment, and this would apply to the 3.2 million children worldwide living with the virus. Significantly, only a quarter of those infected children are believed to have access to the life-saving medicines [19] , and few drugs in the current HIV pharmacopoeia have been specifically designed to fit the paediatric needs. Although new fixed-dose combinations (FDC) are progressively becoming available, no FDC including protease inhibitors (Lopinavir/ritonavir) is currently available in a paediatric-friendly formulation, and as a result, children do not have access to the recommended best treatment policies to address their infection. DNDi has defined the ideal target product profile for paediatric HIV [20] , which includes the need for safe and efficacious drugs, formulated as a suitable product for infants and children in an easy-to-use fixed dose combination, palatable, adapted to tropical climates (and hence stable without the need for refrigeration) and with no drug-drug interactions with drugs used for the treatment of tuberculosis, a common co-infection. The optimum needs required for the chronic treatment of these patients are still far from being reached, but the efforts to develop paediatric drugs for HIV in recent times open a window of optimism.
In addition to issues related to availability and access to paediatric medications, many concerns exist in relation to the quality of the drugs available in low-income settings [21] . Conway et al. recently conducted a review on the quality of 75 paediatric formulations from 28 low-and middle-income countries, and found that in general, antibacterials, antifungals and antiretrovirals were consistently of good quality, although many medications for paediatric use lacked any quality assurance testing. In many cases, substandard medicines were confirmed to be counterfeit, but poor manufacturing or inadequate storage conditions in tropical environments seemed to equally contribute to the decreased quality of drugs. The widespread emergence of substandard or counterfeit medicines has been associated with a significant risk of adverse outcomes [22, 23] , and it therefore behoves the public health community to adequately address this new plague. Further quality studies of paediatric formulations of essential medicines, and in a wider number of countries, are therefore urgently required both to continually monitor drug quality but also to assess the clinical consequences and impact of using the available circulating drugs in these settings.
In this age of extraordinary technological advances in biomedicine, it is unacceptable that newborns and infants from the poorest countries remain vulnerable to the devastating effects of infectious diseases. The inequities of access to health, together with the scarcity of drugs specifically designed to suit the needs of the youngest need to be urgently addressed, in a more harmonized manner, and under the leadership of those who are in the frontline of the problem. This needs to include aggressive measures to monitor the quality of drugs available and to detect and eradicate the use and circulation of substandard and counterfeit drugs. Additionally, the development of paediatric-specific formulations and the clinical trials required to assess these formulations should become an obligation attached to the licensure requirements for any new drug aimed to treat any disease affecting a significant proportion of children. 
